Navigation Links
Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Date:5/27/2009

carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031 and LX1032 and the potential therapeutic and commercial potential of LX1031 and LX1032. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and LX1032 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such for
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
11. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... According to market research report “Outdoor Wi-Fi Market ... Global Advancements, Forecasts and Analysis (2013 - 2018)", ... with analysis and forecasting of the global revenues. ... and the restrains for this market with the ... Browse 65 market data tables and 69 figures ...
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application ... 2019", analyzes the global market on the basis ... industry details such as the key drivers, current ... , Browse 81 Market Data Tables and 29 ... on “1,6-Hexanediol Market by Application and by Geography ...
(Date:10/18/2014)... 18, 2014 The Asia-Pacific Liquid Crystal ... the concerned market in Asia-Pacific with analysis and forecast ... in 2013, and is expected to reach $380.0 million ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. This also provides a ...
(Date:10/18/2014)... According to a new market research report “Hydraulic ... Trends & Forecasts up till 2017”, hydraulic fracturing market ... value is expected to increase from $40 billion in ... during the same period. North America is expected to ... of hydraulic horse power supplied by the year 2011. ...
Breaking Biology Technology:Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4
... NEW YORK, August 28 XTL Biopharmaceuticals,Ltd. (NASDAQ: ... biopharmaceutical company,engaged in the acquisition, development and commercialization ... particularly,neuropathic pain and hepatitis C, today announced that ... Company,s depositary bank,The Bank of New York, will ...
... PARIS, August 28 ExonHit Therapeutics, a drug,and ... discovery,collaboration with Allergan Inc. (NYSE: AGN ), ... reached a success milestone.,As a result of the ... human,clinical testing will be initiated on the first ...
... (Nasdaq:,IDMI) today announced that Jeffrey W. Sherman, M.D., F.A.C.P. ... Senior Vice President,of Research and Development. Dr. Sherman will ... and CEO Timothy P. Walbert. Dr. Sherman brings ... and will lead the regulatory and clinical strategy for ...
Cached Biology Technology:Processing Fees on ADRs to be Waived for two Months 2Processing Fees on ADRs to be Waived for two Months 3ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials 2ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 4IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 5
(Date:10/17/2014)... have shown for the first time how bacteria can ... giving them the opportunity to get tremendous insights into ... study also discovered the bacterial growth in chronic lung ... slowed down by the immune cells. The researchers discovered ... "suffocate" the bacteria, forcing the bacteria to switch to ...
(Date:10/16/2014)... at William and Mary,s Virginia Institute of Marine ... the Environmental Protection Agency to identify the streams ... to develop tools to help local governments and ... depends critically on a dataset of tidal-marsh observations ... Only with this historical baseline can today,s researchers ...
(Date:10/16/2014)... are anything but sustainable: environmental damage to soil ... increasingly evident. Despite their disadvantages, however, monocultures remain ... the sole possibility of achieving higher yields in ... an ecology professor at the University of Zurich, ... forestry. After all, a new study carried out ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... what other babies her age are doing -- she's feeding ... dance." , Lolita Harding is describing her daughter Dave'yana, who ... a thymus transplant she received at Duke University Medical Center ... was the 31st baby to receive such a transplant at ...
... developed a mathematical model of the rate of ... believe this new model improves upon existing models ... subsurface environments, the typical bacteria hangouts. This model ... important bacterial traits. , The swapping of genetic ...
... arm's length won't protect you from catching an infectious ... Technology which reveals airborne viruses can spread far and ... Laboratory for Air Quality and Health, said the study ... travel a metre in the air. , ...
Cached Biology News:Thymus transplants gives hope to babies with fatal immune disease 2Thymus transplants gives hope to babies with fatal immune disease 3Researchers develop way to calculate speed of bacterial sex 2Spreading viruses as we breathe 2
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... to Yersinia pestis This antibody ... . Immunogen: Purified ... vaccine strain EV76. ... F1 capsular antigen. There is no ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Biology Products: